{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:08:41Z","timestamp":1791950921788,"version":"4.3.4"},"reference-count":69,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute megakaryoblastic leukemia (AMKL) is a rare, developmentally restricted, and highly lethal cancer of early childhood. The paucity and hypocellularity (due to myelofibrosis) of primary patient samples hamper the discovery of cell- and genotype-specific treatments. AMKL is driven by mutually exclusive chimeric fusion oncogenes in two-thirds of the cases, with CBFA2T3::GLIS2 (CG2) and NUP98 fusions (NUP98r) representing the highest-fatality subgroups. We established CD34+ cord blood\u2013derived CG2 models (n\u00a0= 6) that sustain serial transplantation and recapitulate human leukemia regarding immunophenotype, leukemia-initiating cell frequencies, comutational landscape, and gene expression signature, with distinct upregulation of the prosurvival factor B-cell lymphoma 2 (BCL2). Cell membrane proteomic analyses highlighted CG2 surface markers preferentially expressed on leukemic cells compared with CD34+ cells (eg, NCAM1 and CD151). AMKL differentiation block in the mega-erythroid progenitor space was confirmed by single-cell profiling. Although CG2 cells were rather resistant to BCL2 genetic knockdown or selective pharmacological inhibition with venetoclax, they were vulnerable to strategies that target the megakaryocytic prosurvival factor BCL-XL (BCL2L1), including in\u00a0vitro and in\u00a0vivo treatment with BCL2\/BCL-XL\/BCL-W inhibitor navitoclax and DT2216, a selective BCL-XL proteolysis-targeting chimera degrader developed to limit thrombocytopenia in patients. NUP98r AMKL were also sensitive to BCL-XL inhibition but not the NUP98r monocytic leukemia, pointing to a lineage-specific dependency. Navitoclax or DT2216 treatment in combination with low-dose cytarabine further reduced leukemic burden in mice. This work extends the cellular and molecular diversity set of human AMKL models and uncovers BCL-XL as a therapeutic vulnerability in CG2 and NUP98r AMKL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2022008899","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T20:24:50Z","timestamp":1695241490000},"page":"112-129","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-0049","authenticated-orcid":false,"given":"Verena","family":"Gress","sequence":"first","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"},{"name":"2Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Roussy","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"},{"name":"2Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Boulianne","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"},{"name":"3Department of Pathology, McGill University, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7648-1021","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Bilodeau","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cardin","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehme","family":"El-Hachem","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-4219","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Lisi","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banafsheh","family":"Khakipoor","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9536-3522","authenticated-orcid":false,"given":"Alexandre","family":"Rouette","sequence":"additional","affiliation":[{"name":"4Molecular Diagnostic Laboratory, Centre Hospitalier Universitaire Sainte-Justine, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azer","family":"Farah","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8988-1286","authenticated-orcid":false,"given":"Louis","family":"Th\u00e9ret","sequence":"additional","affiliation":[{"name":"5Institute for Research in Immunology and Cancer, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-0853","authenticated-orcid":false,"given":"L\u00e9o","family":"Aubert","sequence":"additional","affiliation":[{"name":"5Institute for Research in Immunology and Cancer, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furat","family":"Fatima","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"},{"name":"3Department of Pathology, McGill University, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1661-896X","authenticated-orcid":false,"given":"\u00c9ric","family":"Audemard","sequence":"additional","affiliation":[{"name":"5Institute for Research in Immunology and Cancer, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5993-0331","authenticated-orcid":false,"given":"Pierre","family":"Thibault","sequence":"additional","affiliation":[{"name":"5Institute for Research in Immunology and Cancer, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4039-3131","authenticated-orcid":false,"given":"\u00c9ric","family":"Bonneil","sequence":"additional","affiliation":[{"name":"5Institute for Research in Immunology and Cancer, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalila","family":"Chagraoui","sequence":"additional","affiliation":[{"name":"6Molecular Genetics of Stem Cells Laboratory, Institute for Research in Immunology and Cancer, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Laram\u00e9e","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-2600","authenticated-orcid":false,"given":"Patrick","family":"Gendron","sequence":"additional","affiliation":[{"name":"5Institute for Research in Immunology and Cancer, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loubna","family":"Jouan","sequence":"additional","affiliation":[{"name":"4Molecular Diagnostic Laboratory, Centre Hospitalier Universitaire Sainte-Justine, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7709-1639","authenticated-orcid":false,"given":"Safa","family":"Jammali","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Par\u00e9","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn M.","family":"Simpson","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-6233","authenticated-orcid":false,"given":"Thai Hoa","family":"Tran","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"},{"name":"2Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Duval","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"},{"name":"2Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Teira","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"},{"name":"2Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5507-8310","authenticated-orcid":false,"given":"Henrique","family":"Bittencourt","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"},{"name":"2Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-4644","authenticated-orcid":false,"given":"Raoul","family":"Santiago","sequence":"additional","affiliation":[{"name":"7Division of Hematology-Oncology, Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, QC, Canada"},{"name":"8Centre de recherche du Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Barab\u00e9","sequence":"additional","affiliation":[{"name":"8Centre de recherche du Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, QC, Canada"},{"name":"9Department of Medicine, Faculty of Medicine, Universit\u00e9 Laval, Qu\u00e9bec City, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-7266","authenticated-orcid":false,"given":"Guy","family":"Sauvageau","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"6Molecular Genetics of Stem Cells Laboratory, Institute for Research in Immunology and Cancer, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"10Division of Hematology, Maisonneuve-Rosemont Hospital, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2259-1713","authenticated-orcid":false,"given":"Martin A.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"},{"name":"11Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2267-1353","authenticated-orcid":false,"given":"Jos\u00e9e","family":"H\u00e9bert","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"12Division of Hematology-Oncology and Quebec Leukemia Cell Bank, H\u00f4pital Maisonneuve-Rosemont, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5962-0250","authenticated-orcid":false,"given":"Philippe P.","family":"Roux","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"5Institute for Research in Immunology and Cancer, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"13Department of Pathology and Cell Biology, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1072-7257","authenticated-orcid":false,"given":"Tanja A.","family":"Gruber","sequence":"additional","affiliation":[{"name":"14Department of Pediatrics, Stanford University School of Medicine, Stanford, CA"},{"name":"15Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9095-0066","authenticated-orcid":false,"given":"Vincent-Philippe","family":"Lavall\u00e9e","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"},{"name":"2Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Wilhelm","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"},{"name":"5Institute for Research in Immunology and Cancer, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5364-5924","authenticated-orcid":false,"given":"Sonia","family":"Cellot","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montr\u00e9al, QC, Canada"},{"name":"2Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"issue":"8","key":"2024010912584225500_bib1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2015-05-567859","article-title":"The biology of pediatric acute megakaryoblastic leukemia","volume":"126","author":"Gruber","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2024010912584225500_bib2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.trecan.2017.07.003","article-title":"Pediatric acute megakaryoblastic leukemia: multitasking fusion proteins and oncogenic cooperations","volume":"3","author":"Lopez","year":"2017","journal-title":"Trends Cancer"},{"issue":"10","key":"2024010912584225500_bib3","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ajh.24109","article-title":"Congenital acute megakaryoblastic leukemia","volume":"90","author":"Bain","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"2024010912584225500_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3892\/mco.2023.2614","article-title":"t(1;7;22)(p13;q21;q13) is a novel 3-way variant of t(1;22)(p13;q13) neonatal acute megakaryoblastic leukemia: a case report","volume":"18","author":"Messiaen","year":"2023","journal-title":"Mol Clin Oncol"},{"issue":"12","key":"2024010912584225500_bib5","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1158\/2159-8290.CD-18-1463","article-title":"Ontogenic changes in hematopoietic hierarchy determine pediatric specificity and disease phenotype in fusion oncogene-driven myeloid leukemia","volume":"9","author":"Lopez","year":"2019","journal-title":"Cancer Discov"},{"key":"2024010912584225500_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.critrevonc.2019.04.011","article-title":"The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children","volume":"138","author":"Masetti","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2024010912584225500_bib7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/90054","article-title":"Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia","volume":"28","author":"Ma","year":"2001","journal-title":"Nat Genet"},{"issue":"3","key":"2024010912584225500_bib8","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood.V78.3.748.748","article-title":"The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group study","volume":"78","author":"Carroll","year":"1991","journal-title":"Blood"},{"issue":"3","key":"2024010912584225500_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.3772","article-title":"Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes","volume":"49","author":"de Rooij","year":"2017","journal-title":"Nat Genet"},{"issue":"12","key":"2024010912584225500_bib10","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/leu.2013.87","article-title":"NUP98\/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern","volume":"27","author":"de Rooij","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"2024010912584225500_bib11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/gcc.20308","article-title":"Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene","volume":"45","author":"van Zutven","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"issue":"21","key":"2024010912584225500_bib12","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1182\/bloodadvances.2019030981","article-title":"Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities","volume":"3","author":"Cardin","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2024010912584225500_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/gcc.22532","article-title":"NUP98-BPTF gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy","volume":"57","author":"Roussy","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"issue":"11","key":"2024010912584225500_bib14","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1084\/jem.20121343","article-title":"Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models","volume":"209","author":"Thiollier","year":"2012","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"2024010912584225500_bib15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2012.10.007","article-title":"An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia","volume":"22","author":"Gruber","year":"2012","journal-title":"Cancer Cell"},{"issue":"17","key":"2024010912584225500_bib16","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2012-11-469825","article-title":"CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype","volume":"121","author":"Masetti","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2024010912584225500_bib17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-19-1800","article-title":"Comprehensive transcriptome profiling of cryptic CBFA2T3-GLIS2 fusion-positive AML defines novel therapeutic options: a COG and TARGET pediatric AML study","volume":"26","author":"Smith","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2024010912584225500_bib18","doi-asserted-by":"crossref","first-page":"e157101","DOI":"10.1172\/JCI157101","article-title":"CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target","volume":"132","author":"Le","year":"2022","journal-title":"J\u00a0Clin Invest"},{"key":"2024010912584225500_bib19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fped.2019.00401","article-title":"Pediatric acute myeloid leukemia (AML): from genes to models toward targeted therapeutic intervention","volume":"7","author":"Mercher","year":"2019","journal-title":"Front Pediatr"},{"key":"2024010912584225500_bib20","doi-asserted-by":"crossref","first-page":"1170622","DOI":"10.3389\/fcell.2023.1170622","article-title":"Advances in molecular characterization of pediatric acute megakaryoblastic leukemia not associated with Down syndrome; impact on therapy development","volume":"11","author":"Li","year":"2023","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"2024010912584225500_bib21","doi-asserted-by":"crossref","first-page":"e30251","DOI":"10.1002\/pbc.30251","article-title":"Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: a report from the Children's Oncology Group","volume":"70","author":"Chisholm","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2024010912584225500_bib22","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/emboj.2011.500","article-title":"Myeloid translocation gene 16 is required for maintenance of haematopoietic stem cell quiescence","volume":"31","author":"Fischer","year":"2012","journal-title":"EMBO J"},{"issue":"2","key":"2024010912584225500_bib23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.devcel.2012.12.004","article-title":"Uncoupling VEGFA functions in arteriogenesis and hematopoietic stem cell specification","volume":"24","author":"Leung","year":"2013","journal-title":"Dev Cell"},{"issue":"23","key":"2024010912584225500_bib24","doi-asserted-by":"crossref","first-page":"10235","DOI":"10.1128\/MCB.25.23.10235-10250.2005","article-title":"ETO-2 associates with SCL in erythroid cells and megakaryocytes and provides repressor functions in erythropoiesis","volume":"25","author":"Schuh","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"8","key":"2024010912584225500_bib25","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng2072","article-title":"Loss of GLIS2 causes nephronophthisis in humans and mice by increased apoptosis and fibrosis","volume":"39","author":"Attanasio","year":"2007","journal-title":"Nat Genet"},{"issue":"3","key":"2024010912584225500_bib26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cell.2012.06.032","article-title":"Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL","volume":"150","author":"Wen","year":"2012","journal-title":"Cell"},{"issue":"3","key":"2024010912584225500_bib27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccell.2017.02.006","article-title":"ETO2-GLIS2 hijacks transcriptional complexes to drive cellular identity and self-renewal in pediatric acute megakaryoblastic leukemia","volume":"31","author":"Thirant","year":"2017","journal-title":"Cancer Cell"},{"issue":"22","key":"2024010912584225500_bib28","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.1182\/bloodadvances.2022008503","article-title":"Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugate","volume":"6","author":"Tang","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2024010912584225500_bib29","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/s41467-019-09917-0","article-title":"A\u00a0high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML","volume":"10","author":"Drenberg","year":"2019","journal-title":"Nat Commun"},{"issue":"5","key":"2024010912584225500_bib30","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"2","key":"2024010912584225500_bib31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41419-021-03500-6","article-title":"The application of BH3 mimetics in myeloid leukemias","volume":"12","author":"Parry","year":"2021","journal-title":"Cell Death Dis"},{"issue":"6","key":"2024010912584225500_bib32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-mimetic drugs: blazing the trail for new cancer medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"2024010912584225500_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2024010912584225500_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"2024010912584225500_bib35","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.molcel.2020.05.014","article-title":"Cell death in the origin and treatment of cancer","volume":"78","author":"Strasser","year":"2020","journal-title":"Mol Cell"},{"issue":"24","key":"2024010912584225500_bib36","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: changing the treatment paradigm","volume":"3","author":"Pollyea","year":"2019","journal-title":"Blood Adv"},{"issue":"21","key":"2024010912584225500_bib37","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2217\/fon-2018-0121","article-title":"Accelerating drug development in pediatric cancer: a novel phase I study design of venetoclax in relapsed\/refractory malignancies","volume":"14","author":"Place","year":"2018","journal-title":"Future Oncol"},{"issue":"6","key":"2024010912584225500_bib38","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"2024010912584225500_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/cdd.2017.170","article-title":"Anti-apoptotic BCL-2 family members in development","volume":"25","author":"Opferman","year":"2018","journal-title":"Cell Death Differ"},{"issue":"3","key":"2024010912584225500_bib40","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanmaki","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"2024010912584225500_bib41","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"issue":"4","key":"2024010912584225500_bib42","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"10","key":"2024010912584225500_bib43","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss","year":"2019","journal-title":"Am J Hematol"},{"issue":"11","key":"2024010912584225500_bib44","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2024010912584225500_bib45","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1084\/jem.20110750","article-title":"Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets","volume":"208","author":"Josefsson","year":"2011","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"2024010912584225500_bib46","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"issue":"9","key":"2024010912584225500_bib47","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"issue":"12","key":"2024010912584225500_bib48","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A\u00a0selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat Med"},{"issue":"13","key":"2024010912584225500_bib49","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanmaki","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2024010912584225500_bib68","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1089\/hum.2004.15.976","article-title":"Factors influencing the titer and infectivity of lentiviral vectors","volume":"15","author":"Logan","year":"2004","journal-title":"Hum Gene Ther"},{"issue":"24","key":"2024010912584225500_bib69","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1182\/blood-2014-04-564666","article-title":"Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13","volume":"124","author":"Imren","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2024010912584225500_bib50","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/leu.2016.119","article-title":"A\u00a0recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group","volume":"30","author":"Eidenschink Brodersen","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"2024010912584225500_bib51","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1182\/bloodadvances.2021006835","article-title":"CEACAM1 is a novel culture-compatible surface marker of expanded long-term reconstituting hematopoietic stem cells","volume":"6","author":"Ansari","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2024010912584225500_bib52","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1038\/s41467-020-17549-y","article-title":"Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer","volume":"11","author":"Aubert","year":"2020","journal-title":"Nat Commun"},{"issue":"25","key":"2024010912584225500_bib53","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2016-11-750729","article-title":"EPCR expression marks UM171-expanded CD34(+) cord blood stem cells","volume":"129","author":"Fares","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2024010912584225500_bib54","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1182\/blood.V86.4.1348.bloodjournal8641348","article-title":"Molecular cloning of cDNA encoding a novel platelet-endothelial cell tetra-span antigen, PETA-3","volume":"86","author":"Fitter","year":"1995","journal-title":"Blood"},{"issue":"2","key":"2024010912584225500_bib55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0145-2126(02)00081-4","article-title":"Megakaryoblastic leukemia cell line MOLM-16 derived from minimally differentiated acute leukemia with myeloid\/NK precursor phenotype","volume":"27","author":"Matsuo","year":"2003","journal-title":"Leuk Res"},{"issue":"20","key":"2024010912584225500_bib56","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1182\/bloodadvances.2020002070","article-title":"Morphologic remission status is limited compared to DeltaN flow cytometry: a Children's Oncology Group AAML0531 report","volume":"4","author":"Brodersen","year":"2020","journal-title":"Blood Adv"},{"key":"2024010912584225500_bib57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.exphem.2018.09.004","article-title":"The Human Cell Atlas bone marrow single-cell interactive web portal","volume":"68","author":"Hay","year":"2018","journal-title":"Exp Hematol"},{"issue":"6","key":"2024010912584225500_bib58","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"issue":"1","key":"2024010912584225500_bib59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41419-019-2203-z","article-title":"BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells","volume":"11","author":"Afreen","year":"2020","journal-title":"Cell Death Dis"},{"issue":"24","key":"2024010912584225500_bib60","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1182\/blood-2011-12-398834","article-title":"Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival","volume":"119","author":"Debrincat","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2024010912584225500_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2020000154","article-title":"Therapeutic development and current uses of BCL-2 inhibition","volume":"2020","author":"Roberts","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2024010912584225500_bib62","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41375-022-01800-0","article-title":"High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia","volume":"37","author":"Aid","year":"2023","journal-title":"Leukemia"},{"key":"2024010912584225500_bib63","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.31.478534","article-title":"PDX models of relapsed pediatric AML preserve global gene expression patterns and reveal therapeutic targets","author":"Wunderlich","year":"1  2022","journal-title":"bioRxiv"},{"issue":"11","key":"2024010912584225500_bib64","doi-asserted-by":"crossref","first-page":"e29221","DOI":"10.1002\/pbc.29221","article-title":"Azacitidine and venetoclax for post-transplant relapse in a case of CBFA2T3\/GLIS2 childhood acute myeloid leukaemia","volume":"68","author":"Mishra","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2024010912584225500_bib65","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"2024010912584225500_bib66","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00280-014-2530-9","article-title":"Mechanism-based pharmacokinetic\/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia","volume":"74","author":"Kaefer","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"2024010912584225500_bib67","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/112\/2180560\/blooda_adv-2022-008899-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/112\/2180560\/blooda_adv-2022-008899-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T12:59:24Z","timestamp":1704805164000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/1\/112\/497968\/CBFA2T3-GLIS2-pediatric-acute-megakaryoblastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008899","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}